Sequent Scientific Limited has informed the Exchange regarding Board meeting held on May 20, 2025.
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sequent Scientific's Board met on May 20, 2025 and approved audited financial results for Q4 and FY ended March 31, 2025. On a standalone basis, FY25 revenue from operations rose to ₹1,782.6 million (vs ₹1,685.2 million in FY24), while profit after tax jumped to ₹158 million from just ₹6.3 million. Consolidated revenue grew ~13% to ₹15,513.7 million and the group swung to a consolidated PAT of ₹322.6 million versus a loss of ₹296.2 million in FY24, driven by lower exceptional charges and operational improvements. The Board also appointed BMP & Co. LLP as Secretarial Auditor for five years (FY26–FY30) and chose NOT to recommend any dividend for FY25, citing conservation of resources. Pending approvals continue for the Composite Scheme of Amalgamation involving entities like Viyash Life Sciences, Symed Labs, and others.
Sharp turnaround in profitability — especially at the consolidated level — is a positive signal, but the absence of a dividend and ongoing ₹52.6 million scheme-related transaction costs may temper near-term shareholder returns. Pending the large amalgamation scheme, the stock could see volatility tied to approval timelines.